Next |
home / stock / aim / aim message board
Subject | By | Source | When |
---|---|---|---|
https://www.otcmarkets.com/stock/AIM | mick | investorshub | 04/30/2023 11:44:57 PM |
AIM AIM ImmunoTech Inc | mick | investorshub | 04/30/2023 9:05:07 PM |
AIM AIM ImmunoTech Inc | mick | investorshub | 04/15/2023 3:05:10 PM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/27/2023 12:02:09 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/06/2023 12:10:26 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 02/06/2023 12:10:25 AM |
They have one fda approved drug patent has | lowfloatwayne | investorshub | 01/22/2023 9:17:39 PM |
znewcar1: $AIM 22% v2,3M c.77 f48,082M H.7744 ML.291 YL.6 | znewcar1 | investorshangout | 01/17/2023 10:17:17 PM |
znewcar1: $AIM 26% v1,1M c.4083 f48,082M H.4299 ML.291 | znewcar1 | investorshangout | 01/04/2023 9:19:02 PM |
This company looks like they have some good | Sesh | investorshub | 01/04/2023 7:27:40 AM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 12/18/2022 10:53:13 PM |
$AIM $AIM ImmunoTech Inc | mick | investorshub | 10/23/2022 6:22:44 PM |
$AIM Aerosonic Common Stock ($0.40 Par Value) | mick | investorshub | 08/31/2022 11:32:17 PM |
This is the $AIM I see... | BooDog | investorshub | 08/25/2022 6:11:06 PM |
dis is good stuff Phase 2 Study of Ampligen | mick | investorshub | 08/25/2022 5:57:40 PM |
Aug-18-22 09:05AM | mick | investorshub | 08/25/2022 5:55:00 PM |
$AIM Aerosonic Common Stock ($0.40 Par Value) | mick | investorshub | 08/25/2022 5:52:35 PM |
lot in pipeline too | mick | investorshub | 08/25/2022 5:52:00 PM |
Just stumbled on this one Mick. | BooDog | investorshub | 08/25/2022 11:11:24 AM |
$AIM ImmunoTech to Present at the Virtual Investor | mick | investorshub | 07/17/2022 10:10:17 PM |
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stoc...